Grace Therapeutics Updates GTx-104 Regulatory and Trial Progress

Grace Therapeutics ( (GRCE) ) has issued an update.

On April 27, 2026, Grace Therapeutics updated its corporate presentation, detailing regulatory feedback and development status for its lead programs, particularly GTx-104, a novel intravenous nimodipine designed to address limitations of the long-standing oral standard of care in aneurysmal subarachnoid hemorrhage. The company reported that its pivotal Phase 3 STRIVE-ON safety trial for GTx-104 met its primary endpoint with evidence of benefit versus oral therapy, and that an April 2026 FDA Complete Response Letter identified only chemistry, manufacturing and controls, nonclinical assessment, and contract manufacturing compliance issues, with no clinical deficiencies, setting a defined remediation path expected to shape its regulatory timelines, potential market entry, and positioning in a rare but severe acute brain injury market where GTx-104 holds orphan drug status and multi-layered intellectual property protection.

The regulatory update highlighted that the FDA’s concerns center on leachable data completeness, a targeted toxicology assessment related to excipient exposure, and remediation of cGMP observations at the contract manufacturing organization, rather than on product-specific safety or efficacy. Grace Therapeutics indicated that ongoing data generation, additional preclinical work as needed, and possible manufacturing alternatives are being pursued to enable resubmission of the GTx-104 New Drug Application, developments that are closely watched by stakeholders given the therapy’s potential to displace oral nimodipine as standard of care and to expand the company’s footprint across rare neurological indications, supported by its advancing GTx-102 and GTx-101 programs.

The most recent analyst rating on (GRCE) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Grace Therapeutics stock, see the GRCE Stock Forecast page.

Spark’s Take on GRCE Stock

According to Spark, TipRanks’ AI Analyst, GRCE is a Neutral.

Overall score is held down primarily by weak financial performance (pre-revenue, ongoing losses, and continued cash burn), with an additional near-term headwind from the FDA Complete Response Letter for GTx-104. Offsetting factors include a low-debt balance sheet and moderately constructive technical signals, while valuation remains mixed due to negative earnings and no dividend support.

To see Spark’s full report on GRCE stock, click here.

More about Grace Therapeutics

Grace Therapeutics, Inc. is a biopharmaceutical company focused on developing drug candidates for severe and rare conditions, including neurological and pain indications. Its pipeline includes GTx-104, an intravenous formulation of nimodipine for aneurysmal subarachnoid hemorrhage, as well as GTx-102 for Ataxia Telangiectasia and GTx-101 for postherpetic neuralgia, targeting specialized hospital and orphan markets.

Average Trading Volume: 670,288

Technical Sentiment Signal: Strong Sell

Current Market Cap: $35.59M

For a thorough assessment of GRCE stock, go to TipRanks’ Stock Analysis page.